evidence:  The most common reason for discontinuation was lack of efficacy, and significantly more patients discontinued due to lack of efficacy in the placebo group than in the etoricoxib and naproxen group (25.2%, 12.5%, 10.5%, respectively, p<0.001 vs placebo)
intervention: etoricoxib 90 mg once daily
comparator: placebo
outcome: , or naproxen 500 mg twice daily